#$%^&*AU2020200373A120200213.pdf#####ABSTRACT The present invention provides for novel methods for reducing the serine protease and/or serine protease zymogen content of plasma-derived protein compositions. An embodiment relates to a method for preparing an inter-alpha-trypsin inhibitor (Ial) composition having a reduced amount for a seine protease or a seine protease zymogen, the method comprising the steps of contacting a bloodplasma derived solution containing lal and a seine protease with finely divided silicon dioxide (SiO 2 ) under conditions suitable to bind the Ial and seine protease, separating the SiO 2 from the composition, and eluting the Ial from the SiO 2 . Also provided are methods for manufacturing plasma-derived protein compositions having reduced seine protease and/or seine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilised compositions of plasma-derived proteins having reduced seine protease and/or seine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced seine protease or seine protease zymogen content.WO 2011/150284 PCT/US2011/038247 3/3 Phosphate buffer system: pH =7.5 251000- 0,45 Factor H - 0,4 201000-- 0,35 - 0,3 5c 151000-- 025 - 0,25 c O- 0,2 5 101000- 0,15 S51000-0,1 - 0,05 1000 0 10OmM 50mM 25mM 5mM Phosphate Phosphate Phosphate Phosphate Buffer； Cond. Buffer； Cond. Buffer； Cond. Buffer； Cond. 18.81 mS/cm 10.91 mS/cm 6.08 mS/cm 1.524 mS/cm FIG. 3
